Last reviewed · How we verify
Montelukast buccal film
Montelukast buccal film is a Small molecule drug developed by IntelGenx Corp.. It is currently in Phase 2 development.
At a glance
| Generic name | Montelukast buccal film |
|---|---|
| Sponsor | IntelGenx Corp. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast buccal film CI brief — competitive landscape report
- Montelukast buccal film updates RSS · CI watch RSS
- IntelGenx Corp. portfolio CI
Frequently asked questions about Montelukast buccal film
What is Montelukast buccal film?
Montelukast buccal film is a Small molecule drug developed by IntelGenx Corp..
Who makes Montelukast buccal film?
Montelukast buccal film is developed by IntelGenx Corp. (see full IntelGenx Corp. pipeline at /company/intelgenx-corp).
What development phase is Montelukast buccal film in?
Montelukast buccal film is in Phase 2.
Related
- Manufacturer: IntelGenx Corp. — full pipeline
- Compare: Montelukast buccal film vs similar drugs
- Pricing: Montelukast buccal film cost, discount & access